The Business Research Company’s 2026 market reports feature advanced enhancements such as market attractiveness analysis, total addressable market evaluation, company benchmarking matrices, interactive Excel dashboards, expanded supply chain intelligence, emerging startup coverage, and detailed product insights, delivering more actionable and strategically valuable research.
How Is The Market Value Of The Glycopeptide Antibiotics Market Projected To Expand During 2026–2030?
The glycopeptide antibiotics market size has shown robust expansion over recent years. Its size is expected to increase from $3.78 billion in 2025 to $4.13 billion in 2026, demonstrating a compound annual growth rate (CAGR) of 9.0%. This historical growth can be attributed to factors such as an increase in hospital-acquired infections, the widespread application of vancomycin as a standard therapy, a rising prevalence of gram-positive bacterial infections, the limited availability of alternative antibiotics, and the expansion of inpatient healthcare infrastructure.
The glycopeptide antibiotics market is anticipated to experience substantial expansion over the upcoming years. Its valuation is projected to reach $5.89 billion by 2030, demonstrating a compound annual growth rate (CAGR) of 9.3%. This projected increase during the forecast period is driven by factors such as the proliferation of multidrug-resistant pathogens, a greater uptake of long-acting glycopeptides, an escalating need for antibiotic therapy administered in outpatient and home-based settings, ongoing research and development in advanced glycopeptide formulations, and increasing global healthcare spending. Key trends observed within this period include a heightened reliance on glycopeptides for treating resistant infections, the broadening of the lipoglycopeptide antibiotics range, an increase in hospital usage of intravenous glycopeptides, a sharpened emphasis on optimized dosing and therapeutic monitoring, and more widespread application in severe gram-positive infections.
Download A Free Sample Report For Comprehensive Market Insights:
https://www.thebusinessresearchcompany.com/sample.aspx?id=9444&type=smp
What Core Drivers Are Transforming The Glycopeptide Antibiotics Market?
A rise in gram-positive infections is anticipated to drive the expansion of the glycopeptide antibiotic market in the near future. These infections stem from gram-positive bacteria, including but not limited to Staphylococcus aureus, Streptococcus pneumoniae, and Streptococcus pyogenes. Glycopeptide antibiotics effectively combat numerous gram-positive bacteria by uniquely targeting their cell wall formation. For example, data from June 2023, released by the UK Health Security Agency in its Group A Streptococcal Infections: Report on Seasonal Activity in England 2022–2023, indicated a significant surge in invasive Group A Streptococcus (iGAS) activity. By week 46 of 2023, 509 laboratory-confirmed iGAS notifications were recorded, with a weekly high of 73 cases. This escalation highlights a growing infectious-disease burden, thereby increasing the need for effective antimicrobial treatments throughout the healthcare sector. Consequently, the rising occurrence of gram-positive infections is fueling the glycopeptide antibiotic market.
How Is The Glycopeptide Antibiotics Market Distributed Across Key Segments?
The glycopeptide antibiotics market covered in this report is segmented –
1) By Drug: Vancomycin, Dalbavancin, Oritavancin, Other Drugs
2) By Route of Administration: Oral, Parenteral, Other Routes
3) By Indication: Skin And Structure Infection, Meningitis, Clostridioides Difficile Infection, Enterocolitis, Other Indications
4) By End-User: Hospitals, Specialty Clinics, Homecare, Other End-Users
Subsegments:
1) By Vancomycin: Vancomycin Injection, Vancomycin Oral Solution, Vancomycin Capsules, Vancomycin Powder for Solution
2) By Dalbavancin: Dalbavancin IV (Intravenous) Formulation, Dalbavancin Powder for Injection
3) By Oritavancin: Oritavancin IV (Intravenous) Formulation, Oritavancin Powder for Injection
4) By Other Drugs: Teicoplanin, Glycopeptide and Lipoglycopeptide Antibiotics
Which Trends Are Shaping The Glycopeptide Antibiotics Market Landscape?
Leading companies in the glycopeptide antibiotics market are concentrating on developing innovative products, such as novel glycopeptide scaffolds, to secure a competitive advantage. These novel glycopeptide scaffolds represent structurally unique antibiotic backbones, derived through advanced biosynthetic or natural-product mining methods. For example, in May 2025, a Chinese-European research consortium, a China-based cross-continental expert group, unveiled Saarvienin A. This newly discovered glycopeptide features a halogenated peptide core, an unusual ureido linkage, and five distinct sugar or aminosugar units. Saarvienin A does not bind to the traditional cell-wall target of other glycopeptides, hinting at a potentially novel mechanism, and shows potent in vitro activity against resistant Gram-positive pathogens like MRSA and vancomycin-resistant Enterococcus. While this innovation marks a significant advancement in tackling antibiotic resistance, it faces challenges including its clinical translation, optimization for safety, and scaling up production.
Which Organizations Are Operating Within The Glycopeptide Antibiotics Market?
Major companies operating in the glycopeptide antibiotics market are ANI Pharmaceuticals Inc., Fresenius SE & Co. KGaA, Pfizer Inc., Novartis AG, Hikma Pharmaceuticals Plc., Aurobindo Pharma Limited, Abbvie Inc., Cumberland Pharmaceuticals Inc., Janssen Global, Bristol-Myers Squibb Company, Shenwei Pharmaceutical Hainan Co. Ltd., Zhejiang Hisun Pharmaceutical Co. Ltd., Alvogen, Bayer AG, Merck & Co. Inc., Teva Pharmaceutical Industries Ltd., Sanofi SA, GlaxoSmithKline plc, Johnson & Johnson, AstraZeneca, Boehringer Ingelheim GmbH, Cipla Inc.
Access The Complete Glycopeptide Antibiotics Market Report:
https://www.thebusinessresearchcompany.com/report/glycopeptide-antibiotics-global-market-report
Which Region Leads The Glycopeptide Antibiotics Market By Size?
North America was the largest region in the glycopeptide antibiotics market in 2025. The regions covered in the glycopeptide antibiotics market report are Asia-Pacific, South East Asia, Western Europe, Eastern Europe, North America, South America, Middle East, Africa.
Access Glycopeptide Antibiotics Market Report for Deeper Competitive Insights
https://www.thebusinessresearchcompany.com/sample.aspx?id=9444&type=smp
Browse Through More Reports Similar to the Global Glycopeptide Antibiotics Market 2026, By The Business Research Company
Glycopeptide Antibiotics Market Report 2026
https://www.thebusinessresearchcompany.com/report/glycopeptide-antibiotics-global-market-report
Peptide Antibiotics Market Report 2026
https://www.thebusinessresearchcompany.com/report/peptide-antibiotics-global-market-report
Antibiotics Market Report 2026
https://www.thebusinessresearchcompany.com/report/antibiotics-global-market-report
Get in touch with us:
The Business Research Company: https://www.thebusinessresearchcompany.com/
Americas: +1 310-496-7795
Asia: +44 7882 955267 & +91 8897263534
Europe: +44 7882 955267
Email us at: marketing@tbrc.info
Follow us on:
LinkedIn: https://in.linkedin.com/company/the-business-research-company
YouTube: https://www.youtube.com/channel/UC24_fI0rV8cR5DxlCpgmyFQ
Global Market Model: https://www.thebusinessresearchcompany.com/global-market-model